

1 **Three families of CD4-induced antibodies are associated with the capacity of plasma from**
2 **people living with HIV to mediate ADCC in presence of CD4-mimetics**

3

4 Alexandra Tauzin^{1,2}, Lorie Marchitto^{1,2}, Étienne Bélanger^{1,2}, Mehdi Benlarbi^{1,2}, Guillaume
5 Beaudoin-Bussièrès^{1,2}, Jérémie Prévost^{1,2}, Derek Yang³, Ta-Jung Chiu³, Hung-Ching Chen³,
6 Catherine Bourassa¹, Halima Medjahed¹, Marek K Korzeniowski⁴, Suneetha Gottumukkala⁴,
7 William D. Tolbert⁴, Jonathan Richard^{1,2}, Amos B Smith III³, Marzena Pazgier⁴, Andrés Finzi^{1,2}

8

9 ¹Centre de Recherche du CHUM, Montreal, QC, Canada

10 ²Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal,
11 QC, Canada

12 ³Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia,
13 PA, USA

14 ⁴Infectious Diseases Division, Department of Medicine, Uniformed Services University of the
15 Health Sciences, Bethesda, MD, USA

16

17 Corresponding author: Andrés Finzi, andres.finzi@umontreal.ca

18

19 Running title: PLWH plasma heterogeneity in response to CD4mc

20

21 Abstract word count: 132

22 Text word count: 5539

23

24

25 **ABSTRACT**

26

27 CD4-mimetics (CD4mcs) are small molecule compounds that mimic the interaction of the CD4
28 receptor with HIV-1 envelope glycoproteins (Env). Env from primary viruses normally samples a
29 “closed” conformation which occludes epitopes recognized by CD4-induced (CD4i) non-
30 neutralizing antibodies (nnAbs). CD4mcs induce conformational changes on Env resulting in the
31 exposure of these otherwise inaccessible epitopes. Here we evaluated the capacity of plasma from
32 a cohort of 50 people living with HIV to recognize HIV-1-infected cells and eliminate them by
33 antibody-dependent cellular cytotoxicity (ADCC) in the presence of a potent indoline CD4mc. We
34 observed a marked heterogeneity among plasma samples. By measuring the levels of different
35 families of CD4i Abs, we found that the levels of anti-cluster A, anti-coreceptor binding site and
36 anti-gp41 cluster I antibodies are responsible for plasma-mediated ADCC in presence of CD4mc.

37

38

39 **IMPORTANCE**

40 There are several reasons that make it difficult to target the HIV reservoir. One of them, is the
41 capacity of infected cells to prevent the recognition of HIV-1 envelope glycoproteins (Env) by
42 commonly-elicited antibodies in people living with HIV. Small CD4-mimetic compounds expose
43 otherwise occluded Env epitopes, thus enabling their recognition by non-neutralizing antibodies.
44 A better understanding of the contribution of these antibodies to eliminate infected cells in presence
45 of CD4mc could lead to the development of therapeutic cure strategies.

46

47

48 INTRODUCTION

49

50 The human immunodeficiency virus type 1 (HIV-1) envelope (Env) protein is a trimer of
51 gp120/gp41 heterodimers non-covalently associated and highly glycosylated (1, 2). Env is the sole
52 viral protein expressed at the surface of virions and infected cells and mediates viral entry into
53 target cells. During the entry process, Env undergoes different conformational changes
54 transitioning from its native unliganded “closed” conformation (State-1) (3, 4) to a “partially open”
55 conformation (State-2) upon interaction with a single CD4 receptor to an “open” conformation
56 (State-3) after engagement of its three gp120 subunits to CD4 (5, 6). After interaction with the
57 CCR5 or CXCR4 coreceptor (7, 8) Env releases its gp41 fusion peptide which inserts into the cell
58 membrane, thereby triggering fusion between the virion and the target cell (7).

59

60 After infection, the HIV-1 accessory proteins Nef and Vpu prevent CD4 expression at the surface
61 of infected cells via different mechanisms. Nef acts on CD4 expressed at the surface of infected
62 cells while Vpu acts on newly-synthesized CD4 in the endoplasmic reticulum (ER), leading to
63 lysosomal degradation or ER-associated protein degradation (ERAD), respectively (9, 10). Thus,
64 Env expressed at the surface of infected cells are free of CD4 and therefore samples a “closed”
65 conformation, preventing recognition of the infected cells by commonly elicited CD4-induced
66 (CD4i) non-neutralizing antibodies (nnAbs). These antibodies were shown to eliminate infected
67 cells by antibody-dependent cellular cytotoxicity (ADCC) when Env samples the “open”
68 conformation (11, 12).

69

70 Based on these observations, small CD4-mimetic compounds (CD4mcs) have been used to force
71 Env to adopt more “open” conformations, successfully sensitizing HIV-1-infected cells to ADCC
72 mediated by CD4i Abs and plasma from PLWH (13–17). CD4mcs are HIV-1 entry inhibitors that
73 bind the Phe43 cavity, a highly conserved region of the gp120 (18–21). Binding of CD4mcs to the
74 Phe43 cavity induces conformational changes that allow the exposition of vulnerable CD4i Env
75 epitopes (14, 16, 17, 22–25). To our knowledge, the recently-described indoline CD4mc CJF-III-
76 288 is the most potent CD4mc to sensitize HIV-1-infected cells to ADCC mediated by PLWH
77 plasma (23). We previously reported the role of two families of nnAbs, recognizing the coreceptor
78 binding site (anti-CoRBS Abs) and the cluster A (anti-cluster A Abs) as being important for PLWH
79 plasma to mediate ADCC in presence of CD4mc (14, 17, 24–26). This combination of nnAbs
80 together with the indane BNM-III-170 CD4mc was shown to stabilize a nnAb-vulnerable Env
81 conformation, State-2A (17). Administration of this combination to humanized mice (hu-mice)

82 resulted in a significant decrease in the size of the viral reservoir (25). In addition to these two CD4i
83 Abs, we recently observed that CD4i nnAbs recognizing the cluster I region of the gp41 (anti-gp41
84 cluster I Abs), can mediate potent ADCC and reduce HIV-1 replication in hu-mice when combined
85 with CD4mc (16).

86

87 In this study, we analyzed the capacity of plasma from a cross-sectional cohort of PLWH to
88 recognize HIV-1-infected cells and mediate ADCC in the presence of a CD4mc. We observed a
89 marked heterogeneity which was associated to the levels of anti-cluster A, anti-coreceptor binding
90 site and anti-gp41 cluster I antibodies.

91

92

93 RESULTS

94

95 **CJF-III-288 enhances the capacity of plasma from PLWH to recognize Env at the surface of** 96 **infected cells and to mediate ADCC activity.**

97

98 We previously demonstrated that CD4mc sensitizes HIV-1-infected cells to ADCC mediated by
99 plasma from PLWH (13, 23). However, whether the time post-infection or ART treatment could
100 impact the capacity of these plasma to mediate ADCC in the presence of CD4mc remain to be
101 determined. We therefore evaluated the capacity of plasma from a cross-sectional cohort of PLWH
102 to recognize and eliminate HIV-1-infected cells by ADCC. This cohort of PLWH was separated
103 into five different groups: four groups were composed of donors who were not under antiretroviral
104 therapy (ART) and collected at different time post-infection: 0-100 days post-infection; 101-180
105 days post-infection; 181-365 days post-infection and 2-5 years post-infection. The last group was
106 composed of donors under ART collected 2-5 years post-infection. Basic demographic data of the
107 cohort is summarized in Table 1. Briefly, we infected primary CD4⁺ T cells with the infectious
108 molecular clone (IMC) HIV-1-JRFL and measured the ability of these plasmas to recognize Env
109 expressed at the surface of productively HIV-1-infected cells (CD4^{low} p24⁺) by flow cytometry.
110 Plasma samples weakly recognized infected cells in the presence of the vehicle (DMSO, Figure
111 1A). However, upon addition of the indoline CD4mc CJF-III-288, recognition by all plasma was
112 significantly enhanced. This enhanced recognition translated into a marked increase in ADCC
113 activity (Figure 1B), as measured with a previously described FACS-based ADCC assay (11, 13,
114 27). As expected, recognition of infected cells by plasma samples was significantly associated with

115 their ADCC activity (Figure 1C). Interestingly, we observed a marked heterogeneity in the capacity
116 of tested PLWH plasma to recognize and mediate ADCC in the presence of CD4mc.

117 When comparing the responses within plasmas from the different groups of donors, we observed
118 that CJF-III-288 strongly increased Env recognition and ADCC activity compared to DMSO in all
119 groups (Figure 1D-E). We also observed that the capacity of plasma to recognize Env and to
120 mediate ADCC in presence of CJF-III-288 increased with time after infection in untreated donors.

121

122

123 **Three families of CD4i nnAbs contribute to PLWH plasma ability to mediate ADCC in**
124 **presence of CD4mc.**

125

126 We hypothesized that the differential composition in CD4i nnAbs could potentially explain the
127 observed heterogeneity in the capacity of PLWH plasma to mediate ADCC in the presence of CJF-
128 III-288. Previously, we reported that the combination of anti-CoRBS and anti-cluster A Abs with
129 the indane CD4mc BNM-III-170 can mediate potent ADCC against HIV-1-infected cells both *in*
130 *vitro* and *in vivo* (14, 17, 24–26). More recently, we reported that anti-gp41 cluster I Abs could also
131 mediate ADCC in the presence of CD4mc (16). To better understand the contribution of these
132 families of CD4i nnAbs to ADCC, we measured their levels respectively by indirect ELISA, as
133 described in the material and methods section. All PLWH plasmas had different but detectable anti-
134 cluster A and anti-gp41 cluster I Abs in their plasma (Figure 2A). In contrast, we were unable to
135 detect anti-CoRBS Abs in some donors (Figure 2A). When stratified by groups, only one donor of
136 the 0-100 days post-infection group had detectable anti-CoRBS Abs, and the levels of anti-cluster
137 A Abs were weak compared to the other groups (Figure 2B). In contrast, anti-gp41 cluster I Abs
138 were readily detected in these early samples. The levels of the three families of Abs progressively
139 increased over time and, while the level of anti-gp41 Abs always remained higher than the two
140 other families of Abs, we did not see significant differences between the levels of anti-cluster A
141 and anti-CoRBS Abs after 181 days post-infection. Of note, the capacity of these plasma samples
142 to mediate ADCC correlated with the levels of each of these three families of antibodies in the
143 presence, but not in its absence of CD4mc (Figure 2C-H).

144

145 To evaluate the contribution of anti-CoRBS, anti-cluster A and anti-gp41 cluster I Abs to plasma-
146 mediated ADCC in the presence of CJF-III-288, we performed a Fab fragment competition assay.
147 Briefly, infected cells were preincubated with CJF-III-288 in presence of anti-CoRBS, anti-cluster
148 A or anti-gp41 cluster I Fab fragments, or a combination of the three Fab fragments. In this

149 experimental setting, Fab fragments bind to their respective epitopes exposed by the CD4mc, and
150 therefore prevent the binding of antibodies from the same family present in plasma from PLWH.
151 This inhibits any ADCC activity mediated by Abs recognizing overlapping epitopes. Preincubation
152 with anti-CoRBS Fab fragments but not anti-cluster A or anti-gp41 cluster I Fab fragments
153 decreased the capacity of PLWH plasma to recognize Env in presence of the CD4mc (Figure 3A).
154 Despite their lack of blocking activity individually, anti-cluster A and anti-gp41 cluster I Fab
155 fragments decreased PLWH plasma binding to infected cells when combined with anti-CoRBS Fab
156 fragments, in agreement with a sequential opening of the trimer by CD4mc in combination with
157 CD4i Abs (14). Interestingly, incubation with each of the three Fab fragments decreased ADCC,
158 albeit this difference was significant only in presence of anti-CoRBS Fab fragments (Figure 3B).
159 Combination of the 3 Fab fragments decreased ADCC levels to those observed in the absence of
160 CD4mc, further demonstrating the importance of these three families of antibodies for the
161 elimination of infected cells by ADCC.

162

163

164 **Anti-CoRBS, cluster A and gp41-cluster I antibodies contribute to plasma-mediated**
165 **elimination of autologous primary CD4+ T cells by ADCC.**

166

167 To extend our analysis to primary clinical samples, we expanded CD4+ T cells from different ART-
168 treated PLWH (Table 2) and measured the capacity of each donor's plasma to eliminate autologous
169 endogenously-infected CD4+ T cells by ADCC in presence of the CJF-III-288 CD4mc. Briefly,
170 CD4+ T cells were isolated from PLWH, activated *ex vivo* with PHA-L/IL-2 and viral replication
171 was followed by intracellular p24 staining (Figure 4A). When we detected at least 7% of p24+ cells
172 in the culture, we evaluated the capacity of autologous plasma to recognize and eliminate infected
173 cells by ADCC in presence or absence of CJF-III-288 (Figure 4B-C). In agreement with our *in vitro*
174 experiments, CD4mc addition significantly increased the recognition of infected cells (Figure 4B),
175 and sensitized them to ADCC (Figure 4C). We then performed Fab fragment competition
176 experiments to evaluate the contribution of anti-CoRBS, anti-cluster A and anti-gp41 cluster I Abs
177 from autologous plasma to mediate ADCC. Preincubation with the combination of the three Fab
178 fragments led to a reduction in ADCC activity, albeit to different extents depending on the donor.

179

180

181 **DISCUSSION**

182

183 Env is the only viral antigen expressed at the surface of virions and infected cells, making it the
184 main target of the humoral response (28). However, while antibodies are elicited against Env after
185 HIV-1 infection, only a rare subset of these antibodies - broadly neutralizing antibodies (bNAbs) -
186 effectively recognize Env in its native, “closed” conformation (3, 6). The majority of antibodies
187 commonly induced in PLWH are non-neutralizing and typically recognize regions of Env that are
188 occluded within the unliganded Env trimer (29). Interestingly, epitopes for some nnAbs map to the
189 most conserved regions of Env that are hidden in the unliganded “closed” conformation (18, 30–
190 34). A strategy to harness the inherent potential of these antibodies is to “open-up” Env with
191 CD4mc, thus exposing otherwise hidden epitopes (13, 14, 16, 17). We previously showed that
192 addition of CD4mc sensitize primary infected CD4⁺ T cells to ADCC mediated by autologous
193 plasma (13). We also showed that CD4mc acts in coordination with anti-CoRBS Abs to “open”
194 Env leading to the exposure of cluster A epitope (14, 24). Anti-cluster A Abs binding stabilizes an
195 asymmetric Env conformation (State-2A) leading to the elimination of infected cells by ADCC (14,
196 17, 24, 35). Administration of a cocktail of CD4mc with anti-CoRBS/anti-cluster A Abs or with
197 plasma from PLWH results in the significant reduction of the viral reservoir accompanied by a
198 significant delay in viral rebound in hu-mice (25).

199

200 In this study, we report that anti-CoRBS Abs, anti-cluster A Abs and a third family of nnAbs
201 (against the gp41 cluster I region), play significant roles in the capacity of any given PLWH plasma
202 to mediate ADCC in the presence of CD4mc. As shown in Figure 5, each of these three families of
203 nnAbs targets highly conserved and non-overlapping regions of Env. Anti-CoRBS Abs interact
204 with regions involved in coreceptor binding (mapping to the outer domain of gp120 at the base of
205 V3 loop), which are necessary for the virus to enter host cells. Since they are involved in coreceptor
206 binding, residues forming the CoRBS are invariable among HIV-1 clades (Figure 5). The cluster A
207 region maps to the gp41 interactive face of gp120, within the topological layers of the gp120 inner
208 domain in the C1-C2 regions, contributing to the structural stabilization of the trimer (33, 36, 37).
209 The cluster A region consists of two non-overlapping sub specificities: A32- and C11-epitope
210 regions (both mapped on Figure 5). The A32 region maps exclusively within the inner domain of
211 gp120 and includes residues within the inner domain mobile layer 1 (centered around CD4 induced
212 $\alpha 0$ helix) of the constant region 1 (C1) region and layer 2 (centered around the $\alpha 1$ helix) of the C2
213 region. Residues of the gp120 outer domain and the N- and C-termini of gp120 are not part of the
214 A32 epitope. In contrast, the C11 epitope involves residues of the eight-stranded β -sandwich region

215 of the gp120 inner domain that is formed by docking the gp120 N-terminus to the 7-stranded β -
216 sandwich. The gp120 C1, C2 and eight-stranded β -sandwich regions where cluster A epitopes are
217 located are highly conserved across different HIV-1 isolates (Figure 5). During the transition to the
218 CD4-induced conformation, this region undergoes a significant structural rearrangement (18, 30,
219 32, 33, 38, 39). Finally, anti-gp41 cluster I antibodies recognize a linear epitope in the disulfide
220 loop region (DLR, linking HR1 and HR2 helices) of the principal immunodominant domain (PID)
221 of gp41 (34) (Figure 5). The gp41 sequence recognized by Cluster I Abs 246D and F240 is highly
222 conserved among HIV-1 isolates. F240 has been shown to be broadly cross-reactive and capable
223 of reacting with primary isolates from all clades of HIV-1 (16, 40, 41).

224

225 Our study emphasizes the importance of these nnAb families in the immune response against HIV-
226 1, particularly in the presence of CD4mc, which "opens-up" the Env structure, exposing otherwise
227 hidden epitopes and thus facilitating a more effective immune attack on infected cells. This
228 approach holds promise for improving the immune system's ability to target and eliminate HIV-1-
229 infected cells, potentially contributing to better control of HIV infection. The conserved nature of
230 these epitopes across different HIV-1 strains also suggests that this strategy could be applied cross-
231 clade. Finally, our study suggests that a cocktail comprising monoclonal antibodies against these
232 epitopes, together with a CD4mc, could represent a potent strategy to eliminate HIV-1-infected
233 cells by ADCC.

234

235

236

237 **MATERIALS AND METHODS**

238

239 **Ethics statement**

240 Written informed consent was obtained from all study participants and research adhered to the
241 ethical guidelines of CRCHUM and was reviewed and approved by the CRCHUM institutional
242 review board (ethics committee, approval number MP-02-2024-11734). Research adhered to the
243 standards indicated by the Declaration of Helsinki. All participants were adult and provided
244 informed written consent prior to enrollment in accordance with Institutional Review Board
245 approval.

246

247 **Cell lines and primary cells**

248 293T human embryonic kidney cells (obtained from ATCC) were maintained in Dulbecco's
249 Modified Eagle Medium (DMEM) (Wisent, St. Bruno, QC, Canada) supplemented with 5% fetal
250 bovine serum (FBS) (VWR, Radnor, PA, USA) and 100 U/mL penicillin/streptomycin (Wisent).
251 Human peripheral blood mononuclear cells (PBMCs) from five HIV-negative individuals (four
252 males and a female, age range 46-67 years) and four ART-treated HIV-positive individuals (all
253 males, age range 44-59 years) obtained by leukapheresis and Ficoll density gradient isolation were
254 cryopreserved in liquid nitrogen until further use. CD4⁺ T cells were purified from resting PBMCs
255 by negative selection using immunomagnetic beads per the manufacturer's instructions (StemCell
256 Technologies, Vancouver, BC) and were activated with phytohemagglutinin-L (PHA-L, 10 µg/mL)
257 for 48h and then maintained in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA)
258 complete medium supplemented with 20% FBS, 100 U/mL penicillin/streptomycin and with
259 recombinant IL-2 (rIL-2, 100 U/mL). All cells were maintained at 37°C under 5% CO₂.

260

261 **Human plasma samples**

262 The FRQS-AIDS and Infectious Diseases Network supports a representative cohort of newly-HIV-
263 infected subjects with clinical indication of primary infection [the Montreal Primary HIV Infection
264 Cohort (42, 43)]. Plasma samples were isolated from 50 PLWH and separated in five different
265 groups, depending on infection duration and treatment with ART: plasma samples were obtained
266 from never treated individuals during the acute phase of infection (0-100 days after infection), the
267 early phase of infection (101-180 or 180-365 days after infection) or during the chronic phase of
268 infection (2-5 years after infection). Plasma samples were also obtained from a group of chronically
269 infected individuals (2-5 years after infection) under ART treatment. The demographic parameters
270 of the PLWH cohort is described in Table 1.

271

272 **Small CD4-mimetic**

273 The small-molecule CD4-mimetic compound CJF-III-288 was synthesized as previously described
274 (23). The compound was dissolved in DMSO at a stock concentration of 10 mM and then diluted
275 to 50 μ M in PBS or in RPMI-1640 complete medium for cell-surface staining and for ADCC
276 assays, respectively.

277

278 **Antibodies production and purification**

279 FreeStyle 293F cells (Thermo Fisher Scientific) were grown in FreeStyle 293F medium (Thermo
280 Fisher Scientific) to a density of 1×10^6 cells/mL at 37°C with 8% CO₂ with regular agitation (150
281 rpm). Cells were transfected with plasmids expressing the light and heavy chains of the anti-cluster
282 A A32, the anti-CoRBS 17b or the anti-gp41 cluster I F240 antibodies using ExpiFectamine 293
283 transfection reagent, as directed by the manufacturer (Thermo Fisher Scientific). One week later,
284 the cells were pelleted and discarded. The supernatants were filtered (0.22- μ m-pore-size filter), and
285 antibodies were purified by protein A affinity columns, as directed by the manufacturer (Cytiva,
286 Marlborough, MA, USA). The recombinant protein preparations were dialyzed against phosphate-
287 buffered saline (PBS) and stored in aliquots at -80°C. To assess purity, recombinant proteins were
288 loaded on SDS-PAGE polyacrylamide gels in the presence or absence of β -mercaptoethanol and
289 stained with Coomassie blue.

290 The A32, 17b and F240 Fab fragments were prepared from purified IgG (10 mg/mL) by proteolytic
291 digestion with immobilized papain (Pierce, Rockford, IL) and purified using protein A, followed
292 by gel filtration chromatography on a Superdex 200 16/60 column (Cytiva).

293

294 **Protein production and purification**

295 ID2 was expressed and isolated as previously described (44). Briefly, stable HEK293 cell lines
296 containing the ID2 expression plasmid were cultured for 6–7 days before the collection of the
297 supernatant and passage through a 0.22 μ m filter. Media were then run over an N5-i5 affinity
298 column, washed thoroughly with PBS and protein eluted with 0.1 M glycine at pH3. ID2 was
299 analyzed via SDS-PAGE, dialyzed to PBS and sterile filtered. For gp120_{core} Δ V1V2V3V5
300 production, FreeStyle 293F cells (Invitrogen, Carlsbad, Ca, USA) were grown in FreeStyle 293F
301 medium (Invitrogen) to a density of 1×10^6 cells/ml at 37°C with 8% CO₂ with regular agitation
302 (125 rpm). Cells were transfected with a pCDNA3.1 plasmid encoding codon-optimized His(6)-
303 tagged HIV-1_{YU2} gp120_{core} Δ V1V2V3V5 using the ExpiFectamine™ 293 Transfection Kit as
304 directed by the manufacturer (Invitrogen). One week later, cells were pelleted and discarded. The

305 supernatants were filtered (0.22- μ m-pore-size filter) (ThermoFisher Waltham, MA, USA), and the
306 gp120 glycoproteins were purified by nickel affinity columns according to the manufacturer's
307 instructions (Invitrogen). Fractions containing gp120 were concentrated using Centriprep-30K
308 (EMDMillipore Billerica, MA, USA) centrifugal filter units following the manufacturer
309 instructions. Monomeric gp120 was then purified by FPLC as described (45). Monomeric gp120
310 preparations were dialyzed against PBS and stored in aliquots at -80°C . To assess purity,
311 recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie blue.
312 The gp41 peptide synthesis was previously described (40). The amino acid sequence of the 36-
313 residue peptide of the sequence 583–618 of gp41 (based on the clade B BaL sequence) is gp41_{583–}
314 ₆₁₈: VERYLRDQQLLGIWGC SGKLICTTAVPWNASWSNKS. The peptide was synthesized on
315 an ABI 433A automated peptide synthesizer using the optimized HBTU activation/DIEA *in*
316 *situ* neutralization protocol developed by Kent and colleagues for Boc-chemistry solid phase
317 peptide synthesis (SPPS). After cleavage and deprotection in HF, crude product was precipitated
318 with cold ether and purified to homogeneity by preparative C18 reversed-phase HPLC to afford
319 reduced peptide. The molecular masses were confirmed by electrospray ionization mass
320 spectrometry (ESI-MS). Mass: observed 4082.0 Da, calculated 4081.6 Da. The reduced peptide
321 was dissolved at 0.4 mg/ml in 1 M GuHCl containing 20% DMSO (v/v) for disulfide formation.
322 After 2 hours, reaction was completed and purified with RP-HPLC to afford oxidized peptide. Mass
323 (ESI): observed. 4079.9 Da, calculated. 4079.6 Da.

324

325

326 **Antibodies**

327 The anti-cluster A A32, the anti-CoRBS 17b or the anti-gp41 cluster I F240 antibodies were used
328 as controls in the different ELISA assays. The 17b Fab fragment was used to block anti-CoRBS
329 Abs binding in the anti-CoRBS ELISA assays. Horseradish peroxidase (HRP)-conjugated Ab
330 specific for the Fc region of human IgG (Invitrogen) was used as a secondary Ab to detect Ab
331 binding in ELISA experiments. Alexa Fluor-647-conjugated goat anti-human IgG (Thermo Fisher
332 Scientific) were used as secondary Ab to detect plasma binding in flow cytometry experiments.
333 The A32, 17b and F240 Fab fragments were used to mask the cluster A, CoRBS and cluster I
334 epitopes, respectively, during flow cytometry cell-surface staining and ADCC assays. Anti-human
335 IgG Fc secondary antibodies (Thermo Fisher Scientific) were used when cell surface binding was
336 performed in presence of Fab fragment blockade. The PE-conjugated anti-HIV p24 Ab (Clone
337 KC57-RD1, Beckman Coulter) and the FITC anti-human CD4 OKT4 Antibody (Biolegend) were

338 used to detect productively HIV-1 infected cells in flow cytometry cell-surface staining and ADCC
339 assays (27).

340

341 **Plasmids and proviral constructs**

342 The infectious molecular clone (IMC) of HIV-1_{JRFL} was kindly provided by Dr Dennis Burton (The
343 Scripps Research Institute). The vesicular stomatitis virus G (VSV-G)-encoding plasmid was
344 previously described (46).

345

346 **Viral production**

347 VSV-G-pseudotyped HIV-1 viruses were produced by co-transfection of 293T cells with the HIV-
348 1_{JRFL} proviral construct and a VSV-G-encoding vector at a ratio of 3:2 using the polyethylenimine
349 (PEI) method. Two days post-transfection, cell supernatants were harvested, clarified by low-speed
350 centrifugation (300 × g for 5 min), and concentrated by ultracentrifugation at 4°C (100,605 × g for
351 1h) over a 20% sucrose cushion. Pellets were resuspended in fresh RPMI 1640 complete medium,
352 aliquoted and stored at -80°C until use.

353

354 ***In vitro* infections**

355 VSV-G-pseudotyped HIV-1 viruses were used for *in vitro* infection. Briefly, primary CD4⁺ T cells
356 from HIV-1 negative individuals were isolated from PBMCs, activated for 2 days with PHA-L and
357 then maintained in RPMI 1640 complete medium supplemented with rIL-2. Five to seven days
358 after activation, the cells were spinoculated with the HIV-1_{JRFL} virus at 800 × g for 1h in 96-well
359 plates at 25°C. All viral productions were titrated on primary CD4⁺ T cells to achieve similar levels
360 of infection (around 12% of infected cells).

361

362 ***Ex vivo* expansion of HIV-infected CD4⁺ primary T cells**

363 To expand endogenously infected CD4⁺ T cells, primary CD4⁺ T cells obtained from ART-treated
364 PLWH were isolated from PBMCs by negative selection. CD4⁺ T cells were activated with PHA-
365 L at 10 µg/mL for 48 h and then cultured for several days in RPMI 1640 complete medium
366 supplemented with rIL-2 (100 U/mL). Intracellular anti-p24 staining was performed daily and an
367 ADCC test was done when at least 7% of the cells were p24⁺.

368

369 **Flow cytometry analysis of cell-surface staining**

370 Forty-eight hours after infection, HIV-1-infected primary CD4⁺ T cells were collected, washed
371 with PBS and transferred in 96-well V-bottom plates. The cells were then incubated for 45 min at

372 37°C with plasma (1:1000 dilution) in presence of CJF-III-288 (50 µM) or equivalent dilution of
373 DMSO. Cells were then washed twice with PBS and stained with anti-human IgG Alexa Fluor 647-
374 conjugated secondary antibody (2 µg/mL), FITC-conjugated mouse anti-human CD4 (Clone
375 OKT4) Antibody (1:500 dilution) and AquaVivid viability dye (Thermo Fisher Scientific, Cat#
376 L43957) for 20 min at room temperature. Alternatively, for blockade experiments, HIV-1-infected
377 cells were pre-incubated for 15 minutes at room temperature with DMSO/CJF-III-288 and 17b Fab
378 (20 µg/mL), A32 Fab (20 µg/mL) or F240 Fab (40 µg/mL) or the three Fab fragments together
379 before addition of PLWH plasma. Alexa-Fluor-conjugated anti-human IgG Fc secondary
380 antibodies (1:1500 dilution) were used as secondary antibodies. Cells were then washed twice with
381 PBS and fixed in a 2% PBS-formaldehyde solution. The cells were then permeabilized using the
382 Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, Mississauga, ON, Canada) and
383 stained intracellularly using PE-conjugated mouse anti-p24 mAb (clone KC57; Beckman Coulter,
384 Brea, CA, USA; 1:100 dilution). Samples were acquired on an Fortessa cytometer (BD
385 Biosciences), and data analysis was performed using FlowJo v10.5.3 (Tree Star, Ashland, OR,
386 USA). The percentage of productively infected cells (p24⁺ CD4⁻) was determined by gating on the
387 living cell population according to viability dye staining (Aqua Vivid; Thermo Fisher Scientific).

388

389 **ADCC assay**

390 ADCC activity was measured using a FACS-based infected cell elimination assay 48 hours after
391 infection. The HIV-1-infected primary CD4⁺ T cells were stained with AquaVivid viability dye
392 and cell proliferation dye eFluor670 (Thermo Fisher Scientific) and used as target cells. Resting
393 autologous PBMCs, were stained with cell proliferation dye eFluor450 (Thermo Fisher Scientific)
394 and used as effector cells. The HIV-1-infected primary CD4⁺ T cells were co-cultured with
395 autologous PBMCs (Effector: Target ratio of 10:1) in 96-well V-bottom plates in the presence of
396 plasma from PLWH (dilution 1:1000) and CJF-III-288 (50 µM) or equivalent dilution of DMSO
397 for 5h at 37°C. For blockade experiments, cells were pre-incubated for 15 minutes at room
398 temperature with DMSO/CJF-III-288 and 17b Fab (20 µg/mL), A32 Fab (20 µg/mL) or F240 Fab
399 (40 µg/mL) or the three Fabs before addition of plasma and effector cells. After the 5h incubation,
400 cells were then washed once with PBS and stained with FITC-conjugated mouse anti-human CD4
401 (Clone OKT4) antibody for 20 min at room temperature. Cells were then washed twice with PBS
402 and fixed in a 2% PBS-formaldehyde solution. The cells were then permeabilized and stained
403 intracellularly for p24 as described above. Samples were acquired on a Fortessa cytometer (BD
404 Biosciences), and data analysis was performed using FlowJo v10.5.3 (Tree Star, Ashland, OR,
405 USA). The percentage of infected cells (p24⁺ CD4⁻) was determined by gating on the living cell

406 population according to viability dye staining (Aqua Vivid; Thermo Fisher Scientific). The
407 percentage of ADCC was calculated with the following formula: [(% of p24⁺CD4⁻ cells in Targets
408 plus Effectors) – (% of p24⁺CD4⁻ cells in Targets plus Effectors plus plasma)/(% of p24⁺CD4⁻ cells
409 in Targets) × 100].

410

411 **Anti-cluster A ELISA assay**

412 Recombinant stabilized gp120 inner domain (ID2) exposing the A32 epitope was previously
413 described (33, 44). The recombinant proteins were prepared in PBS at a concentration of 0.1 µg/mL
414 and were adsorbed to white 96-well plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were
415 subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween 20
416 and 2% bovin serum albumin (BSA)) for 1h at room temperature. Wells were then washed four
417 times with washing buffer (TBS containing 0.1% Tween 20). Plasma samples (dilution 1:8000),
418 two-fold serial dilution of anti-cluster A A32 Ab (from 50 to 0.4 ng/mL) to determine concentration
419 using a standard curve, and another dilution of A32 at 1 µg/mL for normalization between plates
420 was prepared in a diluted solution of blocking buffer (0.1% BSA) and incubated with the peptide-
421 coated wells for 90 min at room temperature. Plates were washed four times with washing buffer
422 followed by incubation with HRP-conjugated anti-human IgG secondary Ab (0.3 µg/mL in a
423 diluted solution of blocking buffer [0.4% BSA]) for 1h at room temperature, followed by four
424 washes. HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning
425 Plus-ECL oxidizing and luminol reagents (PerkinElmer Life Sciences). Light emission was
426 measured with an LB942 TriStar luminometer (Berthold Technologies). Signal obtained with BSA
427 was subtracted for each plasma and normalized to the signal obtained with A32 present in each
428 plate. Concentration of the plasma was determined with the A32 standard curve. The seropositivity
429 threshold was established using the following formula: mean of 8 plasma from HIV-1-uninfected
430 individuals + (3 standard deviation of the mean of 8 HIV negative plasma).

431

432

433 **Anti-CoRBS ELISA**

434 Recombinant CD4 bound stabilized gp120 proteins, lacking V1, V2, V3 and V5 regions (gp120_{core}
435 ΔV1V2V3V5) was previously described (25, 33). Proteins were prepared in PBS at a concentration
436 of 0.1 µg/mL and were adsorbed to white 96-well plates (MaxiSorp Nunc) overnight at 4°C. Coated
437 wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1%
438 Tween 20 and 2% BSA) for 1h at room temperature. Wells were then washed four times with
439 washing buffer (TBS containing 0.1% Tween 20). Anti-CoRBS 17b Fab fragment (0.5 µg/mL)

440 were prepared in a diluted solution of blocking buffer (0.1% BSA) and incubated with the half of
441 the peptide-coated wells for 90 min at room temperature. The other half of the plate was incubated
442 with a solution of blocking buffer (0.1% BSA). Wells were then washed four times with washing
443 buffer (TBS containing 0.1% Tween 20). Plasma samples (dilution 1:8000), two-fold serial dilution
444 of anti-CoRBS 17b Ab (from 50 to 0.4 ng/mL) to determine concentration using a standard curve,
445 and another dilution of 17b at 1 µg/mL for normalization between plates was prepared in a diluted
446 solution of blocking buffer (0.1% BSA) and incubated with the peptide-coated wells for 90 min at
447 room temperature. Plates were washed four times with washing buffer followed by incubation with
448 HRP-conjugated anti-human IgG secondary Ab (0.3 µg/mL in a diluted solution of blocking buffer
449 [0.4% BSA]) for 1h at room temperature, followed by four washes. HRP enzyme activity was
450 determined after the addition of a 1:1 mix of Western Lightning Plus-ECL oxidizing and luminol
451 reagents (PerkinElmer Life Sciences). Light emission was measured with an LB942 TriStar
452 luminometer (Berthold Technologies). Signal obtained with BSA was subtracted for each plasma
453 and was then normalized to the signal obtained with 17b present in each plate. Concentration of the
454 plasma was determined with the 17b standard curve. The anti-CoRBS antibody level corresponds
455 to the value obtained when the concentration obtained with 17b Fab preincubation condition is
456 subtracted from that without 17b Fab preincubation condition. The seropositivity threshold was
457 established using the following formula: mean of 8 plasmas from HIV-1-uninfected individuals +
458 (3 standard deviation of the mean of 8 HIV negative plasma).

459

460 **Anti-gp41 cluster I peptide ELISA**

461 Peptides corresponding to the gp41 C-C loop region (residues 583–618) were either previously
462 described (16, 40) or purchased from Genscript (Piscataway, NJ, USA). Peptides were prepared in
463 PBS at a concentration of 0.1 µg/mL and were adsorbed to white 96-well plates (MaxiSorp Nunc)
464 overnight at 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered
465 saline [TBS] containing 0.1% Tween 20 and 2% BSA) for 1 h at room temperature. Wells were
466 then washed four times with washing buffer (TBS containing 0.1% Tween 20). Plasma samples
467 (dilution 1:8000), two-fold serial dilution of anti-gp41 cluster I F240 Ab (from 50 to 0.4 ng/mL) to
468 determine concentration using a standard curve, and another dilution of F240 at 1 µg/mL for
469 normalization between plates was prepared in a diluted solution of blocking buffer (0.1% BSA)
470 and incubated with the peptide-coated wells for 90 min at room temperature. Plates were washed
471 four times with washing buffer followed by incubation with HRP-conjugated anti-human IgG
472 secondary Ab (0.3 µg/mL in a diluted solution of blocking buffer [0.4% BSA]) for 1h at room
473 temperature, followed by four washes. HRP enzyme activity was determined after the addition of

474 a 1:1 mix of Western Lightning Plus-ECL oxidizing and luminol reagents (PerkinElmer Life
475 Sciences). Light emission was measured with an LB942 TriStar luminometer (Berthold
476 Technologies). Signal obtained with BSA was subtracted for each plasma and was then normalized
477 to the signal obtained with F240 present in each plate. Concentration of the plasma was determined
478 with the F240 standard curve. The seropositivity threshold was established using the following
479 formula: mean of 8 plasmas from HIV-1-uninfected individuals + (3 standard deviation of the mean
480 of 8 HIV negative plasma).

481

482 **Sequences analysis**

483 The LOGO plot was created using the Analyze Align tool at the Los Alamos National Laboratory
484 - HIV database which is based on the WebLogo program
485 (https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze_align.html) and the HIV-
486 1 database global curated and filtered 2019 alignment, including 6,223 individual Env protein
487 sequences (47). The relative height of each letter within individual stack represents the frequency
488 of the indicated amino acid at that position. The numbering of Env amino acid sequences is based
489 on the HXB2 reference strain of HIV-1, where 1 is the initial methionine.

490

491 **QUANTIFICATION AND STATISTICAL ANALYSIS**

492 Statistics were analyzed using GraphPad Prism version 10.2.0 (GraphPad, San Diego, CA, USA).
493 Every data set was tested for statistical normality and this information was used to apply the
494 appropriate (parametric or nonparametric) statistical test. Statistical details of experiments are
495 indicated in the figure legends. p values < 0.05 were considered significant; significance values are
496 indicated as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

497

498 **ACKNOWLEDGMENTS**

499 The authors thank the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance,
500 Mario Legault from the FRQS AIDS and Infectious Diseases network for cohort coordination and
501 clinical samples. This study was supported by grants from the National Institutes of Health to A.F.
502 (R01 AI148379, R01 AI150322, AI176531); A.F. and M.P., (R01 AI129769, AI174908). Support
503 for this work was also provided by the NIAID-funded ERASE HIV consortium (UM1 AI-164562)
504 to A.B.S. and A.F., by a CIHR Team Grant #422148, a project grant #451304 and a Canada
505 Foundation for Innovation grant #41027 to A.F. A.F. was supported by a Canada Research Chair
506 on Retroviral Entry #RCHS0235 950-232424. M.B. and G.B-B. are the recipients of CIHR doctoral
507 fellowship. E.B. is a recipient of a CIHR master fellowships. J.P. was the recipients of a CIHR

508 doctoral fellowship. A.T. was supported by a MITACs Elevation post-doctoral fellowship. The
509 funders had no role in study design, data collection and analysis, decision to publish, or preparation
510 of the manuscript.

511

512 **DISCLAIMER**

513 The views expressed in this manuscript are those of the authors and do not reflect the official policy
514 or position of the Uniformed Services University, the U.S. Army, the Department of Defense, the
515 National Institutes of Health, Department of Health and Human Services or the U.S. Government,
516 nor does it mention of trade names, commercial products, or organizations imply endorsement by
517 the U.S. Government.

518 **Figure legends**

519

520 **Figure 1. CJF-III-288 enhances recognition and ADCC-mediated elimination of HIV+**
521 **infected cells by PLWH plasma. (A, D)** HIV+ infected CD4+ T cells recognition by 50 PLWH
522 plasma in presence of CJF-III-288 (50 μ M) or equivalent volume of DMSO. The panel **A** shows
523 the results obtained with the plasma from the 50 PLWH, and the panel **D** shows the results
524 depending on infection duration and treatment with antiretroviral therapy. **(B, E)** PLWH plasma-
525 mediated ADCC in presence of CJF-III-288 (50 μ M) or equivalent volume of DMSO. The panel **B**
526 shows the results obtained with plasma from the 50 PLWH, and the panel **E** shows the results
527 depending on infection duration and treatment with antiretroviral therapy of the individuals. **(C)**
528 Spearman correlation between the capacity of the plasma to recognize the infected cells and to
529 mediate ADCC in presence of DMSO (grey), CJF-III-288 (blue) or both conditions (black). Error
530 bars indicate means \pm SEM (**p < 0.01; ***p < 0.001; ****p < 0.0001). The data shows the mean
531 of 3 independent experiments. Statistical significance was tested using paired t tests or Wilcoxon
532 matched-pairs signed rank test, based on statistical normality.

533

534 **Figure 2. Correlations between the level of three families of non-neutralizing antibodies and**
535 **plasma binding and ADCC activity. (A-B)** Indirect ELISA was performed by incubating plasma
536 samples from 50 PLWH to measure the levels of antibodies recognizing specifically the CoRBS,
537 the cluster A or the gp41 cluster I epitopes (see materials and methods section for more details).
538 CD4i Abs was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values
539 obtained with BSA (negative control) were subtracted and further normalized to the signal obtained
540 with the appropriate control mAb (17b for the CoRBS, A32 for the cluster A and F240 for the gp41
541 cluster I ELISA) present in each plate. The panel **A** shows the results obtained with the plasma
542 from the 50 PLWH, and the panel **B** shows the results depending on infection duration and
543 treatment with antiretroviral therapy of the individuals. **(C-E)** Spearman correlations between the
544 capacity of plasma samples from 50 PLWH to recognize the infected cells in presence of DMSO
545 (gray) or CJF-III-288 at 50 μ M (blue) and the level of anti-CoRBS **(C)**, anti-cluster A **(D)** or anti-
546 gp41 cluster I **(E)** antibodies present in these plasmas. **(F-H)** Spearman or Pearson correlations
547 between the capacity of plasma samples to mediated ADCC in presence of DMSO (gray) or CJF-
548 III-288 at 50 μ M (blue) and the level of anti-CoRBS **(F)**, anti-cluster A **(G)** or anti-gp41 cluster I
549 **(H)** antibodies present in these plasmas. The data shows the mean of 3 independent experiments.
550 Error bars indicate means \pm SEM (*p < 0.05; **p < 0.01; ****p < 0.0001; ns, non-significant).

551 Statistical significance was tested using paired t tests or Wilcoxon matched-pairs signed rank test,
552 based on statistical normality.

553

554 **Figure 3. Anti-CoRBS, anti-cluster A and anti-gp41 cluster I CD4-induced Abs contribute to**
555 **ADCC mediated by plasma from PLWH in presence of a CD4mc.** (A) HIV+ infected CD4+ T
556 cells recognition and (B) ADCC activity of plasma from 20 PLWH (from the two groups of donors,
557 untreated or ART-treated, collected 2-5 years after infection) in presence of DMSO or CJF-III-288
558 (50 μ M, blue) with or without pre-incubation with anti-cluster A A32 Fab, or anti-gp41 cluster I
559 F240 Fab or anti-CoRBS 17b Fab or the three Fab fragments. Error bars indicate means \pm SEM (*p
560 < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, non-significant). Statistical significance was
561 tested using paired t tests, based on statistical normality.

562

563 **Figure 4. ADCC activity of PLWH plasma against autologous *ex vivo* expanded CD4+ T cells**
564 **in presence of CJF-III-288.** (A) HIV+ infected CD4+ T cells isolated from PLWH were expanded
565 *ex vivo*. (B) HIV-1-infected cells recognition at the surface of infected cells by autologous plasma
566 in presence of DMSO (grey), CJF-III-288 (blue) or CJF-III-288 with or without preincubation with
567 the three Fab fragments (red). The graph shows the results obtained for a representative donor. (C)
568 ADCC activity in presence of DMSO (gray) or CJF-III-288 (50 μ M, blue) with autologous plasma
569 after or not pre-incubation with anti-cluster A A32 Fab, anti-gp41 cluster I F240 Fab and anti-
570 CoRBS 17b Fab fragments. Each symbol represent data from an individual donor.

571

572 **Figure 5. Anti-cluster A, anti-CoRBS and anti-gp41 cluster I Abs recognized highly conserved**
573 **epitopes in the Env.** Env residues forming epitopes for cluster A, CoRBS and gp41 cluster I region
574 are highlighted in pink, yellow and cyan, respectively. Epitope residues are defined as gp120
575 (cluster A and CoRBS) or gp41 (cluster I) residues contributing buried surface area to the Fab-Env
576 antigen interface as calculated by PISA (http://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver).
577 Calculations were done based on available Env antigen complexes of cluster A Abs: A32 (PDB
578 code: 4YC2 and 4YBL), N5-i5 (PDB code: 4H8W), 2.2c (PDB code: 4R4F), N60-i3 (PDB code:
579 4RFO), JR4 (PDB code: 4RFN), CH54 (PDB code: 6MG7), CH55 (PDB code: 6OFI), DH677.3
580 (PDB code: 6MFP), C11 (PDB code: 6OEJ), and N12-i3 (PDB code: 5W4L); CoRBS Abs: 17b
581 (PDB code: 1GC1), 48d (PDB code: 4DVR), N12-i2 (PDB code: 6W4M), 412d (PDB code:
582 2QAD), X5 (PDB code: 2B4C); and cluster I Abs: F240 (PDB code: 7N05) and 7B2 (PDB code:
583 4YDV) Cluster I region includes also 246D epitope residues defined based on peptide mapping as
584 in PMID: 1714520.

585 **REFERENCES**

586

587 1. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C,
588 Haseltine W, Sodroski J. 1987. Functional regions of the envelope glycoprotein of human
589 immunodeficiency virus type 1. *Science* 237:1351–1355.

590 2. Freed EO, Martin MA. 1995. The role of human immunodeficiency virus type 1 envelope
591 glycoproteins in virus infection. *J Biol Chem* 270:23883–23886.

592 3. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB,
593 Kwong PD, Blanchard SC, Mothes W. 2014. Conformational dynamics of single HIV-1
594 envelope trimers on the surface of native virions. *Science* 346:759–763.

595 4. Ma X, Lu M, Gorman J, Terry DS, Hong X, Zhou Z, Zhao H, Altman RB, Arthos J, Blanchard
596 SC, Kwong PD, Munro JB, Mothes W. 2018. HIV-1 Env trimer opens through an asymmetric
597 intermediate in which individual protomers adopt distinct conformations. *eLife* 7:e34271.

598 5. Li W, Qin Z, Nand E, Grunst MW, Grover JR, Bess JW, Lifson JD, Zwick MB, Tagare HD,
599 Uchil PD, Mothes W. 2023. HIV-1 Env trimers asymmetrically engage CD4 receptors in
600 membranes. *Nature* 623:1026–1033.

601 6. Lu M, Ma X, Castillo-Menendez LR, Gorman J, Alshafi N, Ermel U, Terry DS, Chambers
602 M, Peng D, Zhang B, Zhou T, Reichard N, Wang K, Grover JR, Carman BP, Gardner MR,
603 Nikic-Spiegel I, Sugawara A, Arthos J, Lemke EA, Smith AB, Farzan M, Abrams C, Munro
604 JB, McDermott AB, Finzi A, Kwong PD, Blanchard SC, Sodroski JG, Mothes W. 2019.
605 Associating HIV-1 envelope glycoprotein structures with states on the virus observed by
606 smFRET. *Nature* 568:415–419.

607 7. Chen B. 2019. Molecular Mechanism of HIV-1 Entry. *Trends Microbiol* 27:878–891.

- 608 8. Shaik MM, Peng H, Lu J, Rits-Volloch S, Xu C, Liao M, Chen B. 2019. Structural basis of
609 coreceptor recognition by HIV-1 envelope spike. *Nature* 565:318–323.
- 610 9. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. 1994. Nef induces CD4 endocytosis:
611 requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
612 *Cell* 76:853–864.
- 613 10. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1
614 Vpu protein induces rapid degradation of CD4. *J Virol* 66:7193–7200.
- 615 11. Veillette M, Désormeaux A, Medjahed H, Gharsallah N-E, Coutu M, Baalwa J, Guan Y, Lewis
616 G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J,
617 Finzi A. 2014. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by
618 antibody-dependent cell-mediated cytotoxicity. *J Virol* 88:2633–2644.
- 619 12. Veillette M, Coutu M, Richard J, Batrville L-A, Dagher O, Bernard N, Tremblay C,
620 Kaufmann DE, Roger M, Finzi A. 2015. The HIV-1 gp120 CD4-bound conformation is
621 preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in
622 sera from HIV-1-infected individuals. *J Virol* 89:545–551.
- 623 13. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schön A, Freire
624 E, Routy J-P, Smith AB, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann DE, Hahn BH,
625 Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A. 2015. CD4 mimetics sensitize HIV-
626 1-infected cells to ADCC. *Proc Natl Acad Sci U S A* 112:E2687-2694.
- 627 14. Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, Tolbert WD, Prévost J,
628 Chapleau J-P, Coutu M, Jia M, Brassard N, Park J, Courter JR, Melillo B, Martin L, Tremblay
629 C, Hahn BH, Kaufmann DE, Wu X, Smith AB, Sodroski J, Pazgier M, Finzi A. 2016. Co-

- 630 receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A
631 ADCC Epitopes on HIV-1 Envelope Glycoproteins. *EBioMedicine* 12:208–218.
- 632 15. Laumaea A, Marchitto L, Ding S, Beaudoin-Bussièrès G, Prévost J, Gasser R, Chatterjee D,
633 Gendron-Lepage G, Medjahed H, Chen H-C, Smith AB, Ding H, Kappes JC, Hahn BH,
634 Kirchhoff F, Richard J, Duerr R, Finzi A. 2023. Small CD4 mimetics sensitize HIV-1-infected
635 macrophages to antibody-dependent cellular cytotoxicity. *Cell Rep* 42:111983.
- 636 16. Prévost J, Anand SP, Rajashekar JK, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-
637 Lepage G, Chen H-C, Chen Y, Horwitz JA, Grunst MW, Zolla-Pazner S, Haynes BF, Burton
638 DR, Flavell RA, Kirchhoff F, Hahn BH, Smith AB, Pazgier M, Nussenzweig MC, Kumar P,
639 Finzi A. 2022. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. *Cell Rep*
640 41:111624.
- 641 17. Alshahafi N, Bakouche N, Kazemi M, Richard J, Ding S, Bhattacharyya S, Das D, Anand SP,
642 Prévost J, Tolbert WD, Lu H, Medjahed H, Gendron-Lepage G, Ortega Delgado GG, Kirk S,
643 Melillo B, Mothes W, Sodroski J, Smith AB, Kaufmann DE, Wu X, Pazgier M, Rouiller I,
644 Finzi A, Munro JB. 2019. An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-
645 Dependent Cellular Cytotoxicity. *Cell Host Microbe* 25:578-587.e5.
- 646 18. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure
647 of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing
648 human antibody. *Nature* 393:648–659.
- 649 19. Melillo B, Liang S, Park J, Schön A, Courter JR, LaLonde JM, Wendler DJ, Princiotta AM,
650 Seaman MS, Freire E, Sodroski J, Madani N, Hendrickson WA, Smith AB. 2016. Small-
651 Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. *ACS Med*
652 *Chem Lett* 7:330–334.

- 653 20. Madani N, Schön A, Princiotta AM, LaLonde JM, Courter JR, Soeta T, Ng D, Wang L, Brower
654 ET, Xiang S-H, Kwon YD, Huang C, Wyatt R, Kwong PD, Freire E, Smith AB, Sodroski J.
655 2008. Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120.
656 *Struct Lond Engl* 1993 16:1689–1701.
- 657 21. Prévost J, Tolbert WD, Medjahed H, Sherburn RT, Madani N, Zoubchenok D, Gendron-
658 Lepage G, Gaffney AE, Grenier MC, Kirk S, Vergara N, Han C, Mann BT, Chénine AL,
659 Ahmed A, Chaiken I, Kirchhoff F, Hahn BH, Haim H, Abrams CF, Smith AB, Sodroski J,
660 Pazgier M, Finzi A. 2020. The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and
661 the CD4 Binding Site. *mBio* 11:e00280-20.
- 662 22. Anang S, Zhang S, Fritschi C, Chiu T-J, Yang D, Smith III AB, Madani N, Sodroski J. V3 tip
663 determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A
664 human immunodeficiency virus (HIV-1) envelope glycoproteins. *J Virol* 97:e01171-23.
- 665 23. Fritschi CJ, Anang S, Gong Z, Mohammadi M, Richard J, Bourassa C, Severino KT, Richter
666 H, Yang D, Chen H-C, Chiu T-J, Seaman MS, Madani N, Abrams C, Finzi A, Hendrickson
667 WA, Sodroski JG, Smith AB. Indoline CD4-mimetic compounds mediate potent and broad
668 HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity. *Proc Natl Acad*
669 *Sci U S A* 120:e2222073120.
- 670 24. Anand SP, Prévost J, Baril S, Richard J, Medjahed H, Chapleau J-P, Tolbert WD, Kirk S, Smith
671 AB, Wines BD, Kent SJ, Hogarth PM, Parsons MS, Pazgier M, Finzi A. 2019. Two Families
672 of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected
673 Cells. *J Virol* 93:e01823-18.
- 674 25. Rajashekar JK, Richard J, Beloor J, Prévost J, Anand SP, Beaudoin-Bussièrès G, Shan L,
675 Herndler-Brandstetter D, Gendron-Lepage G, Medjahed H, Bourassa C, Gaudette F, Ullah I,

- 676 Symmes K, Peric A, Lindemuth E, Bibollet-Ruche F, Park J, Chen H-C, Kaufmann DE, Hahn
677 BH, Sodroski J, Pazgier M, Flavell RA, Smith AB, Finzi A, Kumar P. 2021. Modulating HIV-
678 1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. *Cell Host Microbe*
679 29:904-916.e6.
- 680 26. Beaudoin-Bussières G, Prévost J, Gendron-Lepage G, Melillo B, Chen J, Smith III AB, Pazgier
681 M, Finzi A. 2020. Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are
682 Required to Eliminate HIV-1 Infected Cells. *5. Microorganisms* 8:710.
- 683 27. Richard J, Sannier G, Zhu L, Prévost J, Marchitto L, Benlarbi M, Beaudoin-Bussières G, Sun
684 Y, Hongil K, Chatterjee D, Medjahed H, Bourassa C, Delgado G-G, Dubé M, Kirchhoff F,
685 Hahn BH, Kumar P, Kaufmann DE, Finzi A. 2024. CD4 downregulation precedes Env
686 expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing
687 antibodies. *bioRxiv* <https://doi.org/10.1101/2024.05.01.592003>.
- 688 28. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 Envelope Glycoprotein Biosynthesis,
689 Trafficking, and Incorporation. *J Mol Biol* 410:582–608.
- 690 29. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M,
691 Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE,
692 Shaw GM. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding
693 site. *J Exp Med* 201:1407–1419.
- 694 30. Tolbert WD, Sherburn RT, Van V, Pazgier M. 2019. Structural Basis for Epitopes in the gp120
695 Cluster A Region that Invokes Potent Effector Cell Activity. *Viruses* 11:69.
- 696 31. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X,
697 Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK. 2013. Diverse

698 specificity and effector function among human antibodies to HIV-1 envelope glycoprotein
699 epitopes exposed by CD4 binding. *Proc Natl Acad Sci U S A* 110:E69-78.

700 32. Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang C-C, Kwon YD,
701 Louder RK, Luongo TS, McLellan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS,
702 Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, DeVico AL, Lewis
703 GK, Pazgier M. 2014. Structural definition of an antibody-dependent cellular cytotoxicity
704 response implicated in reduced risk for HIV-1 infection. *J Virol* 88:12895–12906.

705 33. Tolbert WD, Gohain N, Veillette M, Chapleau J-P, Orlandi C, Visciano ML, Ebadi M, DeVico
706 AL, Fouts TR, Finzi A, Lewis GK, Pazgier M. 2016. Paring Down HIV Env: Design and
707 Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC
708 Target of the A32 Region. *Struct England* 24:697–709.

709 34. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. 1991. Epitope mapping of two
710 immunodominant domains of gp41, the transmembrane protein of human immunodeficiency
711 virus type 1, using ten human monoclonal antibodies. *J Virol* 65:4832–4838.

712 35. Vézina D, Gong SY, Tolbert WD, Ding S, Nguyen D, Richard J, Gendron-Lepage G, Melillo
713 B, Smith AB, Pazgier M, Finzi A. 2021. Stabilizing the HIV-1 envelope glycoprotein State 2A
714 conformation. *J Virol* 95:e01620-20, JVI.01620-20.

715 36. Finzi A, Xiang S-H, Pacheco B, Wang L, Haight J, Kassa A, Danek B, Pancera M, Kwong PD,
716 Sodroski J. 2010. Topological layers in the HIV-1 gp120 inner domain regulate gp41
717 interaction and CD4-triggered conformational transitions. *Mol Cell* 37:656–667.

718 37. Ding S, Tolbert WD, Prévost J, Pacheco B, Coutu M, Debbeche O, Xiang S-H, Pazgier M,
719 Finzi A. 2016. A Highly Conserved gp120 Inner Domain Residue Modulates Env
720 Conformation and Trimer Stability. *J Virol* 90:8395–8409.

- 721 38. Rasheed M, Bettadapura R, Bajaj C. 2015. Computational Refinement and Validation Protocol
722 for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b
723 Bound State. *Struct Lond Engl* 1993 23:1138–1149.
- 724 39. Huang C, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang M-Y, Dimitrov DS, Hendrickson
725 WA, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, Kwong PD. 2004. Structural basis
726 of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1
727 coreceptor-binding site on gp120. *Proc Natl Acad Sci U S A* 101:2706–2711.
- 728 40. Gohain N, Tolbert WD, Orlandi C, Richard J, Ding S, Chen X, Bonsor DA, Sundberg EJ, Lu
729 W, Ray K, Finzi A, Lewis GK, Pazgier M. 2016. Molecular basis for epitope recognition by
730 non-neutralizing anti-gp41 antibody F240. *Sci Rep* 6:36685.
- 731 41. Cook JD, Khondker A, Lee JE. 2022. Conformational plasticity of the HIV-1 gp41
732 immunodominant region is recognized by multiple non-neutralizing antibodies. *Commun Biol*
733 5:291.
- 734 42. Fontaine J, Chagnon-Choquet J, Valcke HS, Poudrier J, Roger M, Montreal Primary HIV
735 Infection and Long-Term Non-Progressor Study Groups. 2011. High expression levels of B
736 lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease
737 progression in humans. *Blood* 117:145–155.
- 738 43. Fontaine J, Coutlée F, Tremblay C, Routy J-P, Poudrier J, Roger M, Montreal Primary HIV
739 Infection and Long-Term Nonprogressor Study Groups. 2009. HIV infection affects blood
740 myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. *J*
741 *Infect Dis* 199:1007–1018.
- 742 44. Visciano ML, Gohain N, Sherburn R, Orlandi C, Flinko R, Dashti A, Lewis GK, Tolbert WD,
743 Pazgier M. 2019. Induction of Fc-Mediated Effector Functions Against a Stabilized Inner

- 744 Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region. *Front*
745 *Immunol* 10:677.
- 746 45. Coutu M, Finzi A. 2015. HIV-1 gp120 dimers decrease the overall affinity of gp120
747 preparations for CD4-induced ligands. *J Virol Methods* 215–216:37–44.
- 748 46. Emi N, Friedmann T, Yee JK. 1991. Pseudotype formation of murine leukemia virus with the
749 G protein of vesicular stomatitis virus. *J Virol* 65:1202–1207.
- 750 47. Crooks GE, Hon G, Chandonia J-M, Brenner SE. 2004. WebLogo: a sequence logo generator.
751 *Genome Res* 14:1188–1190.
- 752

Table 1: Characteristics of the cohort of people living with HIV, related to Figures 1, 2 and 3.

Group	Sex		Age (years)	Days since infection	Days between infection and ART initiation	Days since ART initiation	Viral load (copies/mL)	CD4 count (cells/mm ³)
	Female (n)	Male (n)						
0-100 days	0	10	41 (18-55)	68 (42-97)	N/A	N/A	60848 (132-391113)	470 (330-829)
101-180 days	0	10	38 (19-58)	138 (109-177)	N/A	N/A	21663 (6641-195302)	650 (420-1235)
181-365 days	0	10	31 (24-44)	240 (203-314)	N/A	N/A	22785 (1866-260852)	490 (230-770)
2-5 years	1	11	34 (20-51)	1158 (856-1810)	N/A	N/A	292340 (14255-809600)	410 (200-1050)
2-5 years	1	7	34 (21-58)	1012 (792-1612)	744 (19-1375)	386 (192-986)	50 (40-3337)	585 (170-1149)

*Values displayed are medians, with ranges in parentheses.

Table 2: Demographic characterization of PLWH used to expand primary infected CD4+ T cells, related to Figure 4.

Donors	Age	Sex	Time since infection (years)	Time since ART initiation (years)	Plasma viral load
1-4	56 (44-59)	All males	23 (14-34)	7.5 (2-13)	All undetectables

*Values displayed are medians, with ranges in parentheses.




Figure 1




Figure 2









Figure 3

A**B****C****Figure 4**

gp120 (31-121)



Epitopes

cluster A

CoRBS

cluster I gp41

gp120 (201-496)



gp41 (512-656)



Figure 5